What the company does
GC Medical Science makes diagnostic reagents used to detect diseases such as HIV, hepatitis, tuberculosis, and malaria, as well as blood-glucose monitoring devices for diabetes management and dialysis fluids used in treating patients with chronic kidney failure.
Its products are supplied to hospitals, clinics, public health centres, and medical wholesale distributors across Korea. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the majority of its revenue from its diagnostic-reagent division, which spans immune, biochemical, and molecular diagnostics.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$68.1M
- FY2024US$75.3M
- FY2025US$78.6M
Operating profit
- FY2023US$1.3M
- FY2024US$1.7M
- FY2025US$2.1M
Net income
- FY2023US$1.4M
- FY2024US$2.5M
- FY2025US$2.5M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The company distributes diagnostic reagents from global partners including Germany's Diasys alongside its own products, broadening its portfolio beyond what most domestic peers offer.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?